Table 1 Characteristics of study population, stratified by trunk/limb fat ratio less than or equal to 1.5 (no lipodystrophy) or greater than 1.5 (lipodystrophy)
Demographic factors | With lipodystrophy (N = 78) | Without lipodystrophy (N = 88) | P value |
|---|---|---|---|
Age (Mean, SD) | 57.9 (7.3) | 54.7 (11.0) | 0.033 |
Male sex (n, %) | 73 (93.6) | 51 (58.0) | < 0.001 |
Caucasian ethnicity (n, %) | 60 (76.9%) | 51 (57.5%) | 0.010 |
Duration of HIV infection (mean, SD) | 13.8 (6.65) | 12.1 (8.04) | 0.14 |
Concurrent medications (proportion exposed) | |||
Statins | 23 (29.5) | 11 (12.5) | 0.007 |
Fibrates | 22 (28.2) | 8 (9.1) | 0.001 |
Oral anti diabetes | 16 (20.5) | 5 (5.68) | 0.004 |
Antiretrovirals (proportion exposed) | |||
Zidovudine | 62 (79.5) | 56 (63.6) | 0.02 |
Stavudine | 36(46.2) | 26 (29.6) | 0.03 |
Abacavir | 37 (47.4) | 29 (32.9) | 0.06 |
Tenofovir | 56 (71.8) | 58 (65.9) | 0.41 |
Etravirine | 12 (15.4) | 0 (0.0) | < 0.001 |
Atazanavir/r | 35 (44.9) | 35 (39.8) | 0.51 |
Lopinavir/r | 42 (53.8) | 39 (44.3) | 0.22 |
Darunavir/r | 26 (33.3) | 19 (21.6) | 0.089 |
Tipranavir | 5 (6.4) | 1 (1.1) | 0.10 |
Fosamprenavir | 2 (2.6) | 2 (2.3) | 1.0 |
Nelfinavir | 23 (29.5) | 16 (18.2) | 0.086 |
Ritonavir | 31 (39.7) | 21 (23.9) | 0.028 |
Raltegravir | 35 (44.9) | 23 (26.1) | 0.012 |
Elvitegravir | 3 (3.9) | 1 (1.1) | 0.34 |
Dolutegravir | 2 (2.3) | 3 (3.9) | 0.67 |
Maraviroc | 10 (12.8) | 5 (5.7) | 0.11 |
Enfuvirtide | 5 (6.41) | 0 (0.0) | 0.016 |